Published in Proc Natl Acad Sci U S A on June 05, 2006
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature (2010) 13.82
Non-coding RNAs in human disease. Nat Rev Genet (2011) 11.40
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
miRiad roles for the miR-17-92 cluster in development and disease. Cell (2008) 8.02
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
The functional role of long non-coding RNA in human carcinomas. Mol Cancer (2011) 6.37
MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol (2009) 5.92
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med (2012) 5.46
Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res (2008) 5.16
miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol (2008) 4.81
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
MicroRNAs in cancer. Annu Rev Pathol (2009) 4.47
Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A (2009) 4.00
miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther (2007) 3.93
MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer (2011) 3.91
Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol (2006) 3.71
Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle (2009) 3.68
Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A (2007) 3.59
MiRNAs and cancer. Am J Pathol (2009) 3.42
Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol (2010) 3.27
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell (2010) 3.27
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A (2008) 3.08
microRNA involvement in human cancer. Carcinogenesis (2012) 2.98
miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One (2009) 2.97
MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res (2010) 2.83
Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. J Virol (2008) 2.83
MicroRNA biogenesis pathways in cancer. Nat Rev Cancer (2015) 2.67
MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60
Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol (2009) 2.57
Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer (2008) 2.53
Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med (2008) 2.49
MicroRNA MiR-17 retards tissue growth and represses fibronectin expression. Nat Cell Biol (2009) 2.49
MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways. J Virol (2008) 2.45
Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res (2009) 2.43
microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood (2010) 2.37
Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene (2007) 2.36
MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res (2008) 2.35
The mammalian ovary from genesis to revelation. Endocr Rev (2009) 2.31
Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A (2011) 2.21
A microRNA expression signature for cervical cancer prognosis. Cancer Res (2010) 2.14
miR-1 induces growth arrest and apoptosis in malignant mesothelioma. Chest (2013) 2.11
MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response. EMBO J (2009) 2.06
Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl (2008) 2.00
miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem (2011) 1.98
Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol (2011) 1.98
MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One (2010) 1.94
MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood (2010) 1.88
MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer (2009) 1.87
Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer (2009) 1.85
MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell (2011) 1.84
MicroRNAs in tumorigenesis: a primer. Am J Pathol (2007) 1.83
Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma. PLoS One (2010) 1.82
PhenomiR: a knowledgebase for microRNA expression in diseases and biological processes. Genome Biol (2010) 1.79
microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res (2010) 1.76
DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene (2011) 1.76
Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest (2007) 1.72
The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. J Exp Clin Cancer Res (2009) 1.66
microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J (2011) 1.66
CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene (2010) 1.65
MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res (2009) 1.64
MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene (2012) 1.63
MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr Res (2010) 1.61
The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Gut (2015) 1.60
Melanoma MicroRNA signature predicts post-recurrence survival. Clin Cancer Res (2010) 1.59
Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia (2010) 1.58
Identification and pathway analysis of microRNAs with no previous involvement in breast cancer. PLoS One (2012) 1.57
MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas. Am J Pathol (2008) 1.57
DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer (2014) 1.56
The roles of binding site arrangement and combinatorial targeting in microRNA repression of gene expression. Genome Biol (2007) 1.53
Causes and consequences of microRNA dysregulation. Cancer J (2012) 1.51
Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer (2010) 1.50
Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis (2010) 1.50
Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res (2011) 1.49
Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA (2009) 1.48
Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res (2010) 1.48
"Myc'ed messages": myc induces transcription of E2F1 while inhibiting its translation via a microRNA polycistron. PLoS Genet (2007) 1.45
MicroRNA: An emerging therapeutic target and intervention tool. Int J Mol Sci (2008) 1.41
Role of miRNAs in the progression of malignant melanoma. Br J Cancer (2009) 1.41
Circular reasoning: microRNAs and cell-cycle control. Trends Biochem Sci (2008) 1.41
Expression profile of microRNAs in c-Myc induced mouse mammary tumors. Breast Cancer Res Treat (2008) 1.41
MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res (2011) 1.39
Transcriptome and targetome analysis in MIR155 expressing cells using RNA-seq. RNA (2010) 1.39
Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med (2010) 1.39
MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int J Clin Exp Pathol (2009) 1.38
Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis (2011) 1.35
Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma. Blood (2007) 1.34
mir-17-92: a polycistronic oncomir with pleiotropic functions. Immunol Rev (2013) 1.32
microRNA, cell cycle, and human breast cancer. Am J Pathol (2010) 1.32
Concise review: MicroRNA expression in multipotent mesenchymal stromal cells. Stem Cells (2007) 1.32
High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer (2010) 1.32
Detection of let-7a microRNA by real-time PCR in gastric carcinoma. World J Gastroenterol (2007) 1.30
MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma. PLoS One (2010) 1.30
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res (2013) 1.29
The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle (2010) 1.28
Overexpression of dicer as a result of reduced let-7 MicroRNA levels contributes to increased cell proliferation of oral cancer cells. Genes Chromosomes Cancer (2010) 1.27
An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genomics (2008) 1.25
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
The functions of animal microRNAs. Nature (2004) 64.85
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62
Prediction of mammalian microRNA targets. Cell (2003) 53.70
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95
Identification of novel genes coding for small expressed RNAs. Science (2001) 44.44
An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science (2001) 44.16
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature (2001) 38.75
MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 37.83
The nuclear RNase III Drosha initiates microRNA processing. Nature (2003) 35.49
Human MicroRNA targets. PLoS Biol (2004) 34.51
An extensive class of small RNAs in Caenorhabditis elegans. Science (2001) 34.17
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
The microRNA Registry. Nucleic Acids Res (2004) 29.45
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics (2004) 24.18
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
MicroRNA genes are transcribed by RNA polymerase II. EMBO J (2004) 20.65
Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res (2004) 18.86
The Microprocessor complex mediates the genesis of microRNAs. Nature (2004) 17.70
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev (2003) 17.64
Nuclear export of microRNA precursors. Science (2003) 16.59
Argonaute2, a link between genetic and biochemical analyses of RNAi. Science (2001) 15.32
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
Processing of primary microRNAs by the Microprocessor complex. Nature (2004) 14.59
The rde-1 gene, RNA interference, and transposon silencing in C. elegans. Cell (1999) 13.48
Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet (2004) 12.97
miRNAs, cancer, and stem cell division. Cell (2005) 12.15
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell (2006) 11.01
A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res (2005) 10.46
Ribo-gnome: the big world of small RNAs. Science (2005) 10.10
A combined computational-experimental approach predicts human microRNA targets. Genes Dev (2004) 9.82
Genomics of microRNA. Trends Genet (2006) 7.75
Chromosome aberrations in solid tumors. Nat Genet (2003) 7.01
Array comparative genomic hybridization and its applications in cancer. Nat Genet (2005) 6.69
MicroRNAs and cancer. Semin Cancer Biol (2003) 4.72
MicroRNA biogenesis and cancer. Cancer Res (2005) 4.41
SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res (2002) 2.09
1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. Genome Res (2003) 1.90
MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status. Br J Cancer (2003) 1.71
CGHAnalyzer: a stand-alone software package for cancer genome analysis using array-based DNA copy number data. Bioinformatics (2005) 1.16
HES-1 inhibits 17beta-estradiol and heregulin-beta1-mediated upregulation of E2F-1. Oncogene (2004) 1.14
Genomes for medicine. Nature (2004) 1.13
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Cancer immunotherapy comes of age. Nature (2011) 12.35
A combined computational-experimental approach predicts human microRNA targets. Genes Dev (2004) 9.82
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 7.86
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet (2005) 6.70
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst (2008) 6.13
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res (2004) 5.24
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature (2011) 4.07
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther (2007) 3.93
Breast and ovarian cancer. N Engl J Med (2003) 3.84
Laser-capture microdissection. Nat Protoc (2006) 3.80
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol (2006) 3.73
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst (2002) 3.65
In vitro degradation of silk fibroin. Biomaterials (2005) 3.56
Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med (2004) 3.55
Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists. J Cutan Pathol (2004) 3.43
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One (2010) 3.38
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med (2008) 3.35
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res (2013) 3.27
STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res (2006) 3.21
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res (2009) 3.10
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet (2010) 2.95
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol (2008) 2.82
Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest (2008) 2.73
High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res (2005) 2.72
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol (2011) 2.67
A comparison of DNA copy number profiling platforms. Cancer Res (2007) 2.63
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res (2004) 2.51
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest (2010) 2.48
Exome sequencing of a multigenerational human pedigree. PLoS One (2009) 2.48
Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res (2007) 2.45
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 2.43
A mouse model of human L1 retrotransposition. Nat Genet (2002) 2.39
Evolution of sleep quantity, sleep deprivation, mood disturbances, empathy, and burnout among interns. Acad Med (2006) 2.39
A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer (2006) 2.35
MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res (2008) 2.35
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Mechanisms of microRNA deregulation in human cancer. Cell Cycle (2008) 2.30
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res (2007) 2.25
Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res (2002) 2.25
Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol (2011) 2.21
Application of breast cancer risk prediction models in clinical practice. J Clin Oncol (2003) 2.19
Exome sequencing allows for rapid gene identification in a Charcot-Marie-Tooth family. Ann Neurol (2011) 2.09